Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs CCX 354 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms CARAT-2
- Sponsors ChemoCentryx
- 09 Jun 2012 Results presented at the 13th Annual Congress of the European League Against Rheumatism.
- 08 Jun 2012 Results were presented at the 13th Annual Congress of the European League Against Rheumatism (EULAR-2012), according to a ChemoCentryx media release.
- 08 Jun 2012 Data were published online in the "Annals of the Rheumatic Diseases" journal, according to a ChemoCentryx media release.